In September 2025, Manitty reached a major milestone in its mission to transform healthcare through connected diagnostics and artificial intelligence. We are proud to share that Manitty has been officially named a laureate of the France 2030 – Tiers Lieux d’Expérimentation program, a national initiative led by the French Ministry of Health and supported by the Banque des Territoires.
This distinction not only affirms the quality and potential of our technology but also anchors Manitty within one of the most ambitious healthcare innovation frameworks in Europe. It represents recognition at the highest level and provides the opportunity to validate our flagship solution, DeepMo, in real-world clinical environments.
What is France 2030 – Tiers Lieux d’Expérimentation?
France 2030 is the French government’s multi-billion-euro plan designed to make France a leader in key sectors of the future, from energy to space to health. Within this framework, “Tiers Lieux d’Expérimentation” (Third Places of Experimentation) focus on digital health innovation.
The concept is simple yet powerful: create real-world laboratories where startups, researchers, healthcare professionals, and patients can co-design, test, and validate new solutions. Instead of staying confined to labs, innovations are brought into hospitals, clinics, and care pathways. The goal is to accelerate adoption by ensuring technologies prove their value directly in the environments where they will be used.
The 2025 call for projects selected 115 initiatives nationwide. Being one of them is both an honor and a responsibility—especially as healthcare systems worldwide face mounting challenges in efficiency, accessibility, and quality of care.
Why Manitty was chosen ?
At the heart of Manitty’s recognition is DeepMo, our AI-powered remote health monitoring platform. Originally designed to combine biosensing hardware with deep learning software, DeepMo provides continuous monitoring of physiological and neurological signals. It transforms raw data into real-time insights, anomaly detection, and predictive indicators that can support physicians and caregivers in decision-making.
For France 2030, Manitty has been selected under the theme “Optimisation des parcours de soins” (Optimization of Care Pathways). This is a critical issue in modern healthcare: how to ensure patients receive the right care, at the right time, in the most effective and efficient way.
DeepMo addresses this by:
- Providing continuous data rather than episodic snapshots, reducing blind spots in patient monitoring.
- Alerting clinicians to early signs of deterioration, enabling proactive interventions.
- Supporting personalized medicine, by tailoring follow-up and treatments to individual patient profiles.
- Improving patient experience, allowing monitoring outside hospital walls, reducing unnecessary readmissions, and empowering patients in their own care.
These capabilities directly align with France 2030’s goals: to improve outcomes, reduce strain on healthcare resources, and accelerate the safe adoption of digital health innovations.
The significance of this recognition
Being a laureate of the Tiers Lieux d’Expérimentation program means more than a badge of honor. It comes with tangible benefits that will accelerate Manitty’s growth:
1.Clinical Validation in Real Conditions
DeepMo will now be tested and validated in collaboration with healthcare professionals and patients. This step is crucial in moving from promising prototype to widely adopted medical solution.
2. €250,000 in Funding
The award includes a grant of €250,000 dedicated to supporting clinical validation. This funding ensures Manitty can rigorously evaluate DeepMo’s impact, efficiency, and safety in real healthcare pathways.
3. Integration into a National Innovation Network
Manitty now joins a national ecosystem of 115 selected projects. This community fosters collaboration, knowledge sharing, and visibility, making it easier to scale successful innovations.
4. Governmental and Institutional Endorsement
Official recognition by the Ministry of Health enhances credibility with healthcare providers, investors, and international partners. It signals that DeepMo is not just another startup idea, but a solution with potential to transform healthcare at scale.
DeepMo: From Concept to Clinical Impact
The journey of DeepMo exemplifies the evolution of deeptech innovation. Developed from academic research in France, the technology has reached TRL 5 (Technology Readiness Level)—validated in laboratory and relevant environments. With France 2030, it now enters the critical stage of clinical adoption.
The project will focus on demonstrating DeepMo’s ability to:
- Reduce delays in diagnosis by providing continuous monitoring.
- Prevent avoidable hospitalizations through early detection of health deterioration.
- Support multidisciplinary teams with predictive analytics.
- Improve resource allocation, ensuring healthcare systems focus efforts where they are most needed.
By optimizing care pathways, DeepMo aims to create value not only for patients and clinicians but also for healthcare systems under financial and organizational pressure.
Looking Ahead
This recognition is both a milestone and a stepping stone. Over the coming months, Manitty will work closely with healthcare partners to implement and test DeepMo in real clinical settings. The results will provide essential evidence for scaling the solution across France, Europe, and beyond.
At the same time, Manitty continues to build momentum internationally. With recognitions from ENFIELD (Horizon Europe) and participation in events like Slush Starter 2025, we are steadily expanding our network of collaborators, advisors, and investors. Together, these achievements highlight Manitty’s positioning at the intersection of healthcare, AI, and innovation policy.
Conclusion
The healthcare sector is entering a new era—one where digital health solutions must prove their worth not just in theory, but in practice. France 2030’s Tiers Lieux d’Expérimentation embodies this shift, and Manitty is proud to be part of it.
By validating DeepMo in clinical environments, we will demonstrate how AI-powered remote monitoring can optimize care pathways, improve patient outcomes, and build more resilient healthcare systems.
For Manitty, this is more than an award—it is an opportunity to fulfill our mission: turning advanced science into real-world impact for patients, caregivers, and society at large.
